JP2023543137A5 - - Google Patents

Info

Publication number
JP2023543137A5
JP2023543137A5 JP2023514105A JP2023514105A JP2023543137A5 JP 2023543137 A5 JP2023543137 A5 JP 2023543137A5 JP 2023514105 A JP2023514105 A JP 2023514105A JP 2023514105 A JP2023514105 A JP 2023514105A JP 2023543137 A5 JP2023543137 A5 JP 2023543137A5
Authority
JP
Japan
Prior art keywords
dna template
cell
primary immune
immune cells
genome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2023514105A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023543137A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/048066 external-priority patent/WO2022047237A1/en
Publication of JP2023543137A publication Critical patent/JP2023543137A/ja
Publication of JP2023543137A5 publication Critical patent/JP2023543137A5/ja
Withdrawn legal-status Critical Current

Links

JP2023514105A 2020-08-28 2021-08-27 プライミング受容体で操作された免疫細胞 Withdrawn JP2023543137A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063072080P 2020-08-28 2020-08-28
US63/072,080 2020-08-28
PCT/US2021/048066 WO2022047237A1 (en) 2020-08-28 2021-08-27 Engineered immune cells with priming receptors

Publications (2)

Publication Number Publication Date
JP2023543137A JP2023543137A (ja) 2023-10-13
JP2023543137A5 true JP2023543137A5 (cg-RX-API-DMAC7.html) 2024-09-03

Family

ID=80352430

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023514105A Withdrawn JP2023543137A (ja) 2020-08-28 2021-08-27 プライミング受容体で操作された免疫細胞

Country Status (10)

Country Link
US (1) US20230340409A1 (cg-RX-API-DMAC7.html)
EP (1) EP4204575A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023543137A (cg-RX-API-DMAC7.html)
KR (1) KR20230083275A (cg-RX-API-DMAC7.html)
CN (1) CN116529364A (cg-RX-API-DMAC7.html)
AU (1) AU2021334366A1 (cg-RX-API-DMAC7.html)
CA (1) CA3191148A1 (cg-RX-API-DMAC7.html)
IL (1) IL300994A (cg-RX-API-DMAC7.html)
MX (1) MX2023002455A (cg-RX-API-DMAC7.html)
WO (1) WO2022047237A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022093846A1 (en) * 2020-10-26 2022-05-05 Arsenal Biosciences, Inc. Safe harbor loci
JP2025514751A (ja) * 2022-04-20 2025-05-09 アーセナル バイオサイエンシズ インコーポレイテッド 遺伝子発現のサプレッサー及び/または合成経路活性化因子及び/または誘導性ペイロードを含む細胞
EP4504768A2 (en) * 2022-05-17 2025-02-12 Arsenal Biosciences, Inc. Systems of engineered receptors targeting psma and ca9
TW202442689A (zh) 2023-03-03 2024-11-01 美商亞森諾生物科學公司 靶向psma及ca9之系統
EP4680748A1 (en) 2023-03-13 2026-01-21 Arsenal Biosciences, Inc. Synthetic pathway activators
CN121674486A (zh) * 2026-02-10 2026-03-17 潍坊吉涛医学科技有限公司 基于慢病毒载体的羊膜细胞永生化建系方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190130608A (ko) * 2017-03-22 2019-11-22 노파르티스 아게 면역종양학을 위한 조성물 및 방법
EP3703712A4 (en) * 2017-10-30 2021-09-22 PACT Pharma, Inc. EDITING PRIMARY CELL GENES
US20200149070A1 (en) * 2018-04-24 2020-05-14 Ligandal, Inc. Methods and compositions for genome editing
CN110184301B (zh) * 2018-04-28 2023-02-24 辉大(上海)生物科技有限公司 通过Tild-CRISPR实现高效精确的靶向整合
CN115175987A (zh) * 2019-09-23 2022-10-11 明尼苏达大学董事会 基因编辑的免疫细胞和治疗方法
WO2022093846A1 (en) * 2020-10-26 2022-05-05 Arsenal Biosciences, Inc. Safe harbor loci
WO2022204443A1 (en) * 2021-03-24 2022-09-29 Genentech, Inc. Efficient tcr gene editing in t lymphocytes
CA3227759A1 (en) * 2021-08-11 2023-02-16 Sebastien Levesque Mtor-targeted modification and uses thereof

Similar Documents

Publication Publication Date Title
JP2024174943A5 (cg-RX-API-DMAC7.html)
JP2020524998A5 (cg-RX-API-DMAC7.html)
JP2025013879A5 (cg-RX-API-DMAC7.html)
JP2018534950A5 (cg-RX-API-DMAC7.html)
JP2019115348A5 (cg-RX-API-DMAC7.html)
JP2016500262A5 (cg-RX-API-DMAC7.html)
JP2016521975A5 (cg-RX-API-DMAC7.html)
CN110577971B (zh) CRISPR/Sa-SauriCas9基因编辑系统及其应用
US11998567B2 (en) Engineered chimeric guide RNA and uses thereof
AU2021300358A1 (en) Methods and compositions for editing the B2M locus in B cells
WO2021082784A1 (zh) 一种基于腺病毒的基因编辑方法
CN110499335B (zh) CRISPR/SauriCas9基因编辑系统及其应用
WO2025128722A2 (en) Methods and compositions for genomic integration
JP2022527709A5 (cg-RX-API-DMAC7.html)
CN110551761A (zh) CRISPR/Sa-SepCas9基因编辑系统及其应用
Rein et al. Applications of gene editing technologies to cellular therapies
CN110577969B (zh) CRISPR/Sa-SlugCas9基因编辑系统及其应用
CN110551760A (zh) 一种CRISPR/Sa-SeqCas9基因编辑系统和其应用
CN110499334A (zh) CRISPR/SlugCas9基因编辑系统及其应用
CN110551762B (zh) CRISPR/ShaCas9基因编辑系统及其应用
CN110577970B (zh) CRISPR/Sa-SlutCas9基因编辑系统及其应用
CN110577972B (zh) CRISPR/Sa-ShaCas9基因编辑系统及其应用
CN110551763B (zh) CRISPR/SlutCas9基因编辑系统及其应用
US20230272431A1 (en) Methods and compositions for editing the b2m locus in b cells
Epstein et al. 119. Engineering a self-inactivating CRISPR system for AAV vectors